This translocation gives rise to chimeric fusion proteins, collectively named BCR-ABL1, whose constitutively activated tyrosine kinase activity is ultimately responsible for the altered differentiation, uncontrolled replication, and resistance to apoptosis typically displayed by CML cells. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.